---
title: "Lysosomal polygenic risk score (lyso-PRS) and Parkinson’s disease risk across populations"
id: "medrxiv-17-lysosomal-polygenic-risk-score-in-parkinson-s-disease-across-populations"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-lysosomal-polygenic-risk-score-in-parkinson-s-disease-across-populations"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1?rss=1"
published_at: "2026-09-15T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Lysosomal polygenic risk score (lyso-PRS) and Parkinson’s disease risk across populations
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-lysosomal-polygenic-risk-score-in-parkinson-s-disease-across-populations
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1?rss=1)
- **Published At:** 2026-09-15T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Lysosomal dysfunction is implicated in Parkinson’s disease (PD); the study evaluated a **lysosomal polygenic risk score (lyso-PRS)** across multiple ancestries using GP2 Neurobooster array data. - The analysis used Tier 2 GP2 release 11 data comprising 32,054 idiopathic PD (iPD) cases and 18,188 healthy controls across ten ancestries. - Primary aims were to: evaluate lyso-PRS performance for PD risk across populations; compare lyso-PRS between iPD, **GBA1-PD**, non-manifesting GBA1 carriers (NMC), and healthy controls (HC) in Europeans; and assess lyso-PRS associations with clinical outcomes in European PD patients. - lyso-PRS showed the strongest predictive performance in the European test cohort (European-GP2: AUC = 0.602, p = 2.02e-172) and validated in an independent European cohort (European-TUEPAC: AUC = 0.632, p = 5.34e-20). - Performance was lower in non-European ancestries (AUC range reported 0.51–0.59, p < 0.05), indicating reduced accuracy outside European populations. - Within Europeans, lyso-PRS distinguished **GBA1-PD** from healthy controls (AUC = 0.621, p = 7.83e-71) and from NMC (AUC = 0.621, p = 1.05e-18). - In the European-GP2 cohort, higher lyso-PRS associated with earlier age at onset (β = −0.21, p = 0.022) and with higher Unified Parkinson’s Disease Rating Scale (UPDRS) scores (β range 0.32–1.13, all p < 0.05). - Not all associations replicated in the validation cohort; the authors emphasize the need for larger and more diverse cohorts to improve and validate lyso-PRS accuracy across ancestries. - Data availability: GP2 Tier 2 data (release 11) via GP2/AMP PD; European Tuebingen cohort available anonymized on request. Ethical approvals and informed consent were obtained across sites; no competing interests declared.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=a8OKExZXgV3O3ThtEz8cEWK6tczfMnQhpMBFmornkK4-1789516124.8920581-1.2.1.1-VEBnmjmo5nshiOMp6dMZDqujbWmK4GeQ6M0sXcvkSqg8MrOW7yJCBr.FcKzQHYSp) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Lysosomal polygenic risk score in Parkinson's disease across populations. Wenhua Sun, Kathrin Brockmann, Isabel Wurster, Roswitha Kemmner, Benjamin Roeben, Reda Skaiene, Stefanie Lerche, Claudia Schulte, Thomas Gasser, Manuela Tan, the Global Parkinson's Genetic Program (GP2) doi: https://doi.org/10.64898/2026.09.14.26362981 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Wenhua Sun 1 Hertie Institute for Clinical Brain Research, University of Tuebingen and German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wenhua%2BSun%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sun%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWenhua%2BSun%2B) Kathrin Brockmann 1 Hertie Institute for Clinical Brain Research, University of Tuebingen and German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kathrin%2BBrockmann%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Brockmann%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKathrin%2BBrockmann%2B) Isabel Wurster 1 Hertie Institute for Clinical Brain Research, University of Tuebingen and German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Isabel%2BWurster%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wurster%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIsabel%2BWurster%2B) Roswitha Kemmner 1 Hertie Institute for Clinical Brain Research, University of Tuebingen and German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Roswitha%2BKemmner%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kemmner%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARoswitha%2BKemmner%2B) Benjamin Roeben 1 Hertie Institute for Clinical Brain Research, University of Tuebingen and German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Benjamin%2BRoeben%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Roeben%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABenjamin%2BRoeben%2B) Reda Skaiene 1 Hertie Institute for Clinical Brain Research, University of Tuebingen and German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Reda%2BSkaiene%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Skaiene%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AReda%2BSkaiene%2B) Stefanie Lerche 1 Hertie Institute for Clinical Brain Research, University of Tuebingen and German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Stefanie%2BLerche%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lerche%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AStefanie%2BLerche%2B) Claudia Schulte 1 Hertie Institute for Clinical Brain Research, University of Tuebingen and German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Claudia%2BSchulte%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Schulte%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AClaudia%2BSchulte%2B) Thomas Gasser 1 Hertie Institute for Clinical Brain Research, University of Tuebingen and German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2BGasser%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gasser%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThomas%2BGasser%2B) * For correspondence: thomas.gasser@uni-tuebingen.de Manuela Tan 2 Oslo University Hospital, Oslo, Norway * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Manuela%2BTan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tan%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AManuela%2BTan%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1300611/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1300611/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1300611/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1300611/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1300611/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1300611/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Lysosomal dysfunction has been implicated in Parkinson's disease (PD) pathogenesis. However, lysosomal polygenic risk scores (lyso-PRS) have not been evaluated extensively in PD across populations. Objectives: (1) Evaluation of lyso-PRS (lyso-PRS) performance for PD risk across populations; (2) Comparison of lyso-PRS across idiopathic PD (iPD), GBA1-PD, non-manifesting GBA1 carriers (NMC), and healthy controls (HC) in the European population. (3) Assessment of the lyso-PRS association with clinical outcomes in the PD patients of European population. Methods: We analyzed Neurobooster array data from the Global Parkinson's Genetics Program (GP2) dataset, including 32,054 iPD cases and 18,188 healthy controls across ten ancestries. Results: (1) lyso-PRS performed best in Europeans (European-GP2 test cohort: AUC = 0.602, p = 2.02e-172; European-TUEPAC validation cohort: AUC = 0.632, p = 5.34e-20) and worse in other populations (AUC: 0.51-0.59, p ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Written informed consent was obtained from all participants (or their parent/legal guardian in the case of individuals under 16 years of age). For multi-centre studies, each collaborating site secured approval from their local ethics committee, and consent procedures were reviewed by the Operations and Compliance Working Group (OCWG) of GP2 to ensure compliance with international standards and local data-sharing regulations. A list of all participating sites can be found on the GP2 website (https://gp2.org/cohort-dashboard-advanced/). Detailed information on ethics approvals and consent procedures is available on the GP2 website (https://gp2.org/resources/consent-guidelines/). Participants' clinical information and genetic samples were obtained with written consent and appropriate institutional ethical approvals. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Data used in the preparation of this article were obtained from the Global Parkinson's Genetics Program (GP2; https://gp2.org). Specifically, we used Tier 2 data from GP2 release 11 (https://zenodo.org/records/17753486). GP2 data are available on AMP PD (https://amp-pd.org). Data of European Tuebingen Parkinson cohort dataset are available in an anonymized format on request to: kathrin.brockmann{at}uni-tuebingen.de. ## Funder Information Declared China Scholarship Council program, 202207040033 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.14.26362982v1 "Moderate-to-vigorous physical activity, age-dependent adiposity, and obesity risk in older adults at high cardiovascular risk")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.14.26362969v1 "Victimisation, depression and suicidal ideation: understanding interlinkages among youth in North India through structural equation modelling") Posted September 15, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/15/2026.09.14.26362981.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.14.26362981v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/15/2026.09.14.26362981.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Lysosomal polygenic risk score in Parkinson's disease across populations. Wenhua Sun, Kathrin Brockmann, Isabel Wurster, Roswitha Kemmner, Benjamin Roeben, Reda Skaiene, Stefanie Lerche, Claudia Schulte, Thomas Gasser, Manuela Tan, the Global Parkinson's Genetic Program (GP2) medRxiv 2026.09.14.26362981; doi: https://doi.org/10.64898/2026.09.14.26362981 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.14.26362981v1%26text%3DLysosomal%2520polygenic%2520risk%2520score%2520in%2520Parkinson%2527s%2520disease%2520across%2520populations. "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.14.26362981v1%26t%3DLysosomal%2520polygenic%2520risk%2520score%2520in%2520Parkinson%2527s%2520disease%2520across%2520populations. "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.14.26362981v1%26title%3DLysosomal%2520polygenic%2520risk%2520score%2520in%2520Parkinson%2527s%2520disease%2520across%2520populations.%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.14.26362981v1%26title%3DLysosomal%2520polygenic%2520risk%2520score%2520in%2520Parkinson%2527s%2520disease%2520across%2520populations. "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.14.26362981) ## Subject Area * [Genetic and Genomic Medicine ](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (617) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (901) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (331) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4811) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (479) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (415) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (649) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1626) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15941) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1202) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7046) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (733) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1064) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5044) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1434) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1765) * [Hematology](https://www.medrxiv.org/collection/hematology) (585) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1344) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16290) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/int
## Related Clinical Research

- [Reduced added sugar in the first 1,000 days tied to lower Alzheimer’s and dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-cutting-added-sugar-before-age-2-linked-to-lower-dementia-depression-risk-in.md)
- [More REM (dream) sleep linked to lower risk of 83 diseases—UK Biobank study](https://medichelpline.com/clinical-feed/medical-news-today-0-more-dream-sleep-linked-to-lower-risk-of-83-diseases-including-diabetes.md)
- [Startup to test psychedelic-like drug for Parkinson’s apathy — STAT+ report](https://medichelpline.com/clinical-feed/stat-news-0-stat-new-startup-to-test-psychedelic-like-drug-against-parkinson-s-symptom.md)
- [Pre-diagnostic 1-year prevalence of polypharmacy and PIMcog in Norwegian outpatients with MCI or d](https://medichelpline.com/clinical-feed/plos-one-14-one-year-pre-diagnostic-prevalence-and-associated-factors-of-polypharmacy-and.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.